{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:45:23Z","timestamp":1784673923383,"version":"3.55.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01532-3","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:04:16Z","timestamp":1761645856000},"page":"676-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Computational design of synthetic receptors with programmable signalling activity for enhanced cancer T cell therapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Jan A.","family":"Rath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4753-8890","authenticated-orcid":false,"given":"Lucas S. P.","family":"Rudden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Nouraee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany X. Y.","family":"Que","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Von Gunten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashashvi","family":"Bhugowon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-5981","authenticated-orcid":false,"given":"Andreas","family":"Fueglistaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2471-0296","authenticated-orcid":false,"given":"Aisima","family":"Chatzi Souleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0744-6844","authenticated-orcid":false,"given":"Patrick","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6440-9970","authenticated-orcid":false,"given":"Caroline","family":"Arber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"1532_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"1532_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"1532_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","volume":"24","author":"A Mulvey","year":"2025","unstructured":"Mulvey, A., Trueb, L., Coukos, G. & Arber, C. Novel strategies to manage CAR-T cell toxicity. Nat. Rev. Drug Discov. 24, 379\u2013397 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1532_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1532_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1532_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1532_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"1532_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1532_CR9","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1532_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1532_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"1532_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1532_CR13","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner, J., Wickman, E., DeRenzo, C. & Gottschalk, S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol. Ther. 28, 2320\u20132339 (2020).","journal-title":"Mol. Ther."},{"key":"1532_CR14","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo, S. P. et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet 403, 1460\u20131471 (2024).","journal-title":"Lancet"},{"key":"1532_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227\u2013242 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"1532_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri.2016.80","volume":"16","author":"DE Speiser","year":"2016","unstructured":"Speiser, D. E., Ho, P. C. & Verdeil, G. Regulatory circuits of T cell function in cancer. Nat. Rev. Immunol. 16, 599\u2013611 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"1532_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41589-021-00926-z","volume":"18","author":"J Manhas","year":"2022","unstructured":"Manhas, J., Edelstein, H. I., Leonard, J. N. & Morsut, L. The evolution of synthetic receptor systems. Nat. Chem. Biol. 18, 244\u2013255 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1532_CR18","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41589-018-0046-z","volume":"14","author":"L Scheller","year":"2018","unstructured":"Scheller, L., Strittmatter, T., Fuchs, D., Bojar, D. & Fussenegger, M. Generalized extracellular molecule sensor platform for programming cellular behavior. Nat. Chem. Biol. 14, 723\u2013729 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1532_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd9994","volume":"372","author":"R Divine","year":"2021","unstructured":"Divine, R. et al. Designed proteins assemble antibodies into modular nanocages. Science 372, eabd9994 (2021).","journal-title":"Science"},{"key":"1532_CR20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41586-021-03258-z","volume":"591","author":"A Quijano-Rubio","year":"2021","unstructured":"Quijano-Rubio, A. et al. De novo design of modular and tunable protein biosensors. Nature 591, 482\u2013487 (2021).","journal-title":"Nature"},{"key":"1532_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41587-019-0403-9","volume":"38","author":"G Giordano-Attianese","year":"2020","unstructured":"Giordano-Attianese, G. et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nat. Biotechnol. 38, 426\u2013432 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1532_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41586-020-03120-8","volume":"589","author":"AJ Ben-Sasson","year":"2021","unstructured":"Ben-Sasson, A. J. et al. Design of biologically active binary protein 2D materials. Nature 589, 468\u2013473 (2021).","journal-title":"Nature"},{"key":"1532_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1126\/science.abd9909","volume":"370","author":"L Cao","year":"2020","unstructured":"Cao, L. et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. Science 370, 426\u2013431 (2020).","journal-title":"Science"},{"key":"1532_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8182","volume":"371","author":"AA Vorobieva","year":"2021","unstructured":"Vorobieva, A. A. et al. De novo design of transmembrane beta barrels. Science 371, eabc8182 (2021).","journal-title":"Science"},{"key":"1532_CR25","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1126\/science.aav7541","volume":"363","author":"M Mravic","year":"2019","unstructured":"Mravic, M. et al. Packing of apolar side chains enables accurate design of highly stable membrane proteins. Science 363, 1418\u20131423 (2019).","journal-title":"Science"},{"key":"1532_CR26","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1128\/MCB.06787-11","volume":"32","author":"CA Hyde","year":"2012","unstructured":"Hyde, C. A. et al. Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites. Mol. Cell. Biol. 32, 3802\u20133813 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"1532_CR27","doi-asserted-by":"publisher","first-page":"12960","DOI":"10.1073\/pnas.1301415110","volume":"110","author":"VM Leppanen","year":"2013","unstructured":"Leppanen, V. M. et al. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proc. Natl Acad. Sci. USA 110, 12960\u201312965 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1532_CR28","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.cell.2015.02.011","volume":"160","author":"I Moraga","year":"2015","unstructured":"Moraga, I. et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell 160, 1196\u20131208 (2015).","journal-title":"Cell"},{"key":"1532_CR29","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.aaw3242","volume":"367","author":"S Wilmes","year":"2020","unstructured":"Wilmes, S. et al. Mechanism of homodimeric cytokine receptor activation and dysregulation by oncogenic mutations. Science 367, 643\u2013652 (2020).","journal-title":"Science"},{"key":"1532_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-065X.2012.01160.x","volume":"250","author":"ST Walsh","year":"2012","unstructured":"Walsh, S. T. Structural insights into the common gamma-chain family of cytokines and receptors from the interleukin-7 pathway. Immunol. Rev. 250, 303\u2013316 (2012).","journal-title":"Immunol. Rev."},{"key":"1532_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.add1219","volume":"381","author":"T Cai","year":"2023","unstructured":"Cai, T., Lenoir Capello, R., Pi, X., Wu, H. & Chou, J. J. Structural basis of gamma chain family receptor sharing at the membrane level. Science 381, 569\u2013576 (2023).","journal-title":"Science"},{"key":"1532_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41422-022-00755-2","volume":"33","author":"G Du","year":"2023","unstructured":"Du, G. et al. Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation. Cell Res. 33, 131\u2013146 (2023).","journal-title":"Cell Res."},{"key":"1532_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cell.2012.12.032","volume":"152","author":"NF Endres","year":"2013","unstructured":"Endres, N. F. et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152, 543\u2013556 (2013).","journal-title":"Cell"},{"key":"1532_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8380","volume":"6","author":"DM Freed","year":"2015","unstructured":"Freed, D. M., Alvarado, D. & Lemmon, M. A. Ligand regulation of a constitutively dimeric EGF receptor. Nat. Commun. 6, 7380 (2015).","journal-title":"Nat. Commun."},{"key":"1532_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41589-019-0407-2","volume":"16","author":"KM Chen","year":"2020","unstructured":"Chen, K. M., Keri, D. & Barth, P. Computational design of G protein-coupled receptor allosteric signal transductions. Nat. Chem. Biol. 16, 77\u201386 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1532_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41586-020-2379-5","volume":"584","author":"J Yin","year":"2020","unstructured":"Yin, J. et al. Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane. Nature 584, 125\u2013129 (2020).","journal-title":"Nature"},{"key":"1532_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis, L. M. & Hicklin, D. J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579\u2013591 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"1532_CR38","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.3389\/fimmu.2019.02019","volume":"10","author":"W Lin","year":"2019","unstructured":"Lin, W. et al. Function of CSF1 and IL34 in macrophage homeostasis, inflammation, and cancer. Front. Immunol. 10, 2019 (2019).","journal-title":"Front. Immunol."},{"key":"1532_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1172\/JCI75876","volume":"125","author":"C Arber","year":"2015","unstructured":"Arber, C. et al. Survivin-specific T cell receptor targets tumor but not T cells. J. Clin. Invest. 125, 157\u2013168 (2015).","journal-title":"J. Clin. Invest."},{"key":"1532_CR40","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2017-02-769463","volume":"130","author":"CD Nishimura","year":"2017","unstructured":"Nishimura, C. D. et al. c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. Blood 130, 2739\u20132749 (2017).","journal-title":"Blood"},{"key":"1532_CR41","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1073\/pnas.0914052107","volume":"107","author":"Y Yang","year":"2010","unstructured":"Yang, Y., Xie, P., Opatowsky, Y. & Schlessinger, J. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Proc. Natl Acad. Sci. USA 107, 1906\u20131911 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1532_CR42","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.str.2015.06.019","volume":"23","author":"J Felix","year":"2015","unstructured":"Felix, J. et al. Structure and assembly mechanism of the signaling complex mediated by human CSF-1. Structure 23, 1621\u20131631 (2015).","journal-title":"Structure"},{"key":"1532_CR43","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.38089","volume":"7","author":"RD Ferrao","year":"2018","unstructured":"Ferrao, R. D., Wallweber, H. J. & Lupardus, P. J. Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation. eLife 7, e38089 (2018).","journal-title":"eLife"},{"key":"1532_CR44","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1073\/pnas.1211560110","volume":"110","author":"JP Defour","year":"2013","unstructured":"Defour, J. P. et al. Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc. Natl Acad. Sci. USA 110, 2540\u20132545 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1532_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.cell.2012.12.030","volume":"152","author":"A Arkhipov","year":"2013","unstructured":"Arkhipov, A. et al. Architecture and membrane interactions of the EGF receptor. Cell 152, 557\u2013569 (2013).","journal-title":"Cell"},{"key":"1532_CR46","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81521","volume":"12","author":"JP Defour","year":"2023","unstructured":"Defour, J. P. et al. Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers. eLife 12, e81521 (2023).","journal-title":"eLife"},{"key":"1532_CR47","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1074\/jbc.REV119.009457","volume":"295","author":"JM Westerfield","year":"2020","unstructured":"Westerfield, J. M. & Barrera, F. N. Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them. J. Biol. Chem. 295, 1792\u20131814 (2020).","journal-title":"J. Biol. Chem."},{"key":"1532_CR48","doi-asserted-by":"publisher","first-page":"e1003742","DOI":"10.1371\/journal.pcbi.1003742","volume":"10","author":"A Arkhipov","year":"2014","unstructured":"Arkhipov, A., Shan, Y., Kim, E. T. & Shaw, D. E. Membrane interaction of bound ligands contributes to the negative binding cooperativity of the EGF receptor. PLoS Comput. Biol. 10, e1003742 (2014).","journal-title":"PLoS Comput. Biol."},{"key":"1532_CR49","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker, W. & Constantinescu, S. N. JAK\/STAT signaling in hematological malignancies. Oncogene 32, 2601\u20132613 (2013).","journal-title":"Oncogene"},{"key":"1532_CR50","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/sj.bjc.6603923","volume":"97","author":"C Kut","year":"2007","unstructured":"Kut, C., Mac Gabhann, F. & Popel, A. S. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br. J. Cancer 97, 978\u2013985 (2007).","journal-title":"Br. J. Cancer"},{"key":"1532_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fimmu.2014.00489","volume":"5","author":"D Laoui","year":"2014","unstructured":"Laoui, D., Van Overmeire, E., De Baetselier, P., Van Ginderachter, J. A. & Raes, G. Functional relationship between tumor-associated macrophages and macrophage colony-stimulating factor as contributors to cancer progression. Front. Immunol. 5, 489 (2014).","journal-title":"Front. Immunol."},{"key":"1532_CR52","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck, M., Remon, J. & Hellmann, M. D. First-line immunotherapy for non-small-cell lung cancer. J. Clin. Oncol. 40, 586\u2013597 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1532_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ejcts.2003.11.031","volume":"25","author":"A Iwasaki","year":"2004","unstructured":"Iwasaki, A., Kuwahara, M., Yoshinaga, Y. & Shirakusa, T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur. J. Cardiothorac. Surg. 25, 443\u2013448 (2004).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1532_CR54","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/mt.2012.210","volume":"21","author":"KK Chow","year":"2013","unstructured":"Chow, K. K. et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol. Ther. 21, 629\u2013637 (2013).","journal-title":"Mol. Ther."},{"key":"1532_CR55","first-page":"7907","volume":"63","author":"KT Coffman","year":"2003","unstructured":"Coffman, K. T. et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 63, 7907\u20137912 (2003).","journal-title":"Cancer Res."},{"key":"1532_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005091","volume":"10","author":"N Camviel","year":"2022","unstructured":"Camviel, N. et al. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. J. Immunother. Cancer 10, e005091 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1532_CR57","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman, Y. et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 3, e270 (2006).","journal-title":"PLoS Med."},{"key":"1532_CR58","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani, A. D. et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108, 3472\u20133476 (2006).","journal-title":"Blood"},{"key":"1532_CR59","doi-asserted-by":"publisher","first-page":"25293","DOI":"10.1073\/pnas.1913541116","volume":"116","author":"DS Svoboda","year":"2019","unstructured":"Svoboda, D. S. et al. Human iPSC-derived microglia assume a primary microglia-like state after transplantation into the neonatal mouse brain. Proc. Natl Acad. Sci. USA 116, 25293\u201325303 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1532_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam, N. et al. Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat. Commun. 11, 283 (2020).","journal-title":"Nat. Commun."},{"key":"1532_CR61","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","volume":"487","author":"A Leaver-Fay","year":"2011","unstructured":"Leaver-Fay, A. et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol. 487, 545\u2013574 (2011).","journal-title":"Methods Enzymol."},{"key":"1532_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas, J. et al. Robust deep learning-based protein sequence design using ProteinMPNN. Science 378, 49\u201356 (2022).","journal-title":"Science"},{"key":"1532_CR63","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"1532_CR64","doi-asserted-by":"publisher","unstructured":"Goudy, O. J., Nallathambi, A., Kinjo, T., Randolph, N. & Kuhlman, B. In silico evolution of protein binders with deep learning models for structure prediction and sequence design. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.05.03.539278 (2023).","DOI":"10.1101\/2023.05.03.539278"},{"key":"1532_CR65","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.abj8754","volume":"373","author":"M Baek","year":"2021","unstructured":"Baek, M. et al. Accurate prediction of protein structures and interactions using a three-track neural network. Science 373, 871\u2013876 (2021).","journal-title":"Science"},{"key":"1532_CR66","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-021-03828-1","volume":"596","author":"K Tunyasuvunakool","year":"2021","unstructured":"Tunyasuvunakool, K. et al. Highly accurate protein structure prediction for the human proteome. Nature 596, 590\u2013596 (2021).","journal-title":"Nature"},{"key":"1532_CR67","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1126\/science.adg7731","volume":"381","author":"F Praetorius","year":"2023","unstructured":"Praetorius, F. et al. Design of stimulus-responsive two-state hinge proteins. Science 381, 754\u2013760 (2023).","journal-title":"Science"},{"key":"1532_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2023.1107400","volume":"11","author":"Q Liu","year":"2023","unstructured":"Liu, Q. & Perez, A. Assessing a computational pipeline to identify binding motifs to the alpha2beta1 integrin. Front. Chem. 11, 1107400 (2023).","journal-title":"Front. Chem."},{"key":"1532_CR69","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41586-023-05696-3","volume":"614","author":"AH Yeh","year":"2023","unstructured":"Yeh, A. H. et al. De novo design of luciferases using deep learning. Nature 614, 774\u2013780 (2023).","journal-title":"Nature"},{"key":"1532_CR70","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71\u201375 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1532_CR71","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"1532_CR72","doi-asserted-by":"publisher","unstructured":"Haubner, S. et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2023.09.010 (2023).","DOI":"10.1016\/j.ccell.2023.09.010"},{"key":"1532_CR73","doi-asserted-by":"publisher","first-page":"25538","DOI":"10.1074\/jbc.M110.127951","volume":"285","author":"S Wilkie","year":"2010","unstructured":"Wilkie, S. et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285, 25538\u201325544 (2010).","journal-title":"J. Biol. Chem."},{"key":"1532_CR74","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen, A. M. et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22, 1211\u20131220 (2014).","journal-title":"Mol. Ther."},{"key":"1532_CR75","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1158\/2159-8290.CD-17-1298","volume":"8","author":"S Sukumaran","year":"2018","unstructured":"Sukumaran, S. et al. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov. 8, 972\u2013987 (2018).","journal-title":"Cancer Discov."},{"key":"1532_CR76","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nchembio.2565","volume":"14","author":"ZL Chang","year":"2018","unstructured":"Chang, Z. L. et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat. Chem. Biol. 14, 317\u2013324 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1532_CR77","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/2159-8290.CD-20-0896","volume":"11","author":"S Lange","year":"2021","unstructured":"Lange, S. et al. A chimeric GM-CSF\/IL18 receptor to sustain CAR T-cell function. Cancer Discov. 11, 1661\u20131671 (2021).","journal-title":"Cancer Discov."},{"key":"1532_CR78","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov. 7, 1238\u20131247 (2017).","journal-title":"Cancer Discov."},{"key":"1532_CR79","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","volume":"8","author":"M Bell","year":"2024","unstructured":"Bell, M. et al. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling. Nat. Biomed. Eng. 8, 380\u2013396 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1532_CR80","doi-asserted-by":"publisher","first-page":"e1000714","DOI":"10.1371\/journal.pcbi.1000714","volume":"6","author":"T Nugent","year":"2010","unstructured":"Nugent, T. & Jones, D. T. Predicting transmembrane helix packing arrangements using residue contacts and a force-directed algorithm. PLoS Comput. Biol. 6, e1000714 (2010).","journal-title":"PLoS Comput. Biol."},{"key":"1532_CR81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00018-021-04112-1","volume":"79","author":"T Hegedus","year":"2022","unstructured":"Hegedus, T., Geisler, M., Lukacs, G. L. & Farkas, B. Ins and outs of AlphaFold2 transmembrane protein structure predictions. Cell. Mol. Life Sci. 79, 73 (2022).","journal-title":"Cell. Mol. Life Sci."},{"key":"1532_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40426-3","volume":"14","author":"P Lin","year":"2023","unstructured":"Lin, P., Yan, Y., Tao, H. & Huang, S. Y. Deep transfer learning for inter-chain contact predictions of transmembrane protein complexes. Nat. Commun. 14, 4935 (2023).","journal-title":"Nat. Commun."},{"key":"1532_CR83","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"1532_CR84","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.ade2574","volume":"379","author":"Z Lin","year":"2023","unstructured":"Lin, Z. et al. Evolutionary-scale prediction of atomic-level protein structure with a language model. Science 379, 1123\u20131130 (2023).","journal-title":"Science"},{"key":"1532_CR85","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12859-022-04873-x","volume":"23","author":"M Bernhofer","year":"2022","unstructured":"Bernhofer, M. & Rost, B. TMbed: transmembrane proteins predicted through language model embeddings. BMC Bioinform. 23, 326 (2022).","journal-title":"BMC Bioinform."},{"key":"1532_CR86","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/mt.2013.110","volume":"21","author":"S Kakarla","year":"2013","unstructured":"Kakarla, S. et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol. Ther. 21, 1611\u20131620 (2013).","journal-title":"Mol. Ther."},{"key":"1532_CR87","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.celrep.2016.09.092","volume":"17","author":"MC Gundry","year":"2016","unstructured":"Gundry, M. C. et al. Highly efficient genome editing of murine and human hematopoietic progenitor cells by CRISPR\/Cas9. Cell Rep. 17, 1453\u20131461 (2016).","journal-title":"Cell Rep."},{"key":"1532_CR88","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/nmeth.3543","volume":"12","author":"MA Moreno-Mateos","year":"2015","unstructured":"Moreno-Mateos, M. A. et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat. Methods 12, 982\u2013988 (2015).","journal-title":"Nat. Methods"},{"key":"1532_CR89","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","volume":"9","author":"Z Yi","year":"2018","unstructured":"Yi, Z., Prinzing, B. L., Cao, F., Gottschalk, S. & Krenciute, G. Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma. Mol. Ther. Methods Clin. Dev. 9, 70\u201380 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1532_CR90","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-1-4939-1789-1_3","volume":"1233","author":"HF Turk","year":"2015","unstructured":"Turk, H. F. & Chapkin, R. S. Analysis of epidermal growth factor receptor dimerization by BS(3) cross-linking. Methods Mol. Biol. 1233, 25\u201334 (2015).","journal-title":"Methods Mol. Biol."},{"key":"1532_CR91","doi-asserted-by":"crossref","unstructured":"Rath, J. A. et al. Designed allosteric biosensors for engineered T cell therapy against cancer. GitHub https:\/\/github.com\/barth-lab\/Dimeric_MultiDomain_Biosensor_Builder (2025).","DOI":"10.1101\/2025.03.14.643388"}],"updated-by":[{"DOI":"10.1038\/s41551-025-01592-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000}}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01532-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01532-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:02:35Z","timestamp":1776808955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01532-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":91,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1532"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01532-3","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"26 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41551-025-01592-5","URL":"https:\/\/doi.org\/10.1038\/s41551-025-01592-5","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.B. holds patents in the field of protein engineering. C.A. holds patents in the field of engineered T cell therapies. C.A. and P.B. hold patents and provisional patent applications in the field of engineered T cell therapies. J.A.R. and L.S.P.R. hold a provisional patent application in the field of engineered T cell therapies. C.A. receives licensing fees and royalties from Immatics (through previous institution Baylor College of Medicine), participated in advisory boards for Kite\/Gilead, Janssen and Celgene\/BMS, and received sponsored travel from Gilead (through current institution University Hospital Lausanne). The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}